Pharming Group N.V. ADR (PHAR)

$12.48 +0.23 (1.88%)
Market Cap 839.31M
Revenue (ttm) 297.20M
Net Income (ttm) -11.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.98%
Debt to Equity Ratio 0.02
Volume 6,700
Avg Vol 5,040
Day's Range N/A - N/A
Shares Out 68.52M
Stochastic %K 100%
Beta 0.02
Analysts Strong Sell
Price Target $30.67

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 71 524 7400
Fax: 31 71 524 7445
Address:
Darwinweg 24, Leiden, Netherlands
SannieVerraderlijk
SannieVerraderlijk Aug. 6 at 8:15 AM
$ABVX $PHAR Will start building bigger positions in EU bio's on any dips
0 · Reply
Longterm007
Longterm007 Aug. 5 at 6:45 AM
$PHAR exact, en als in 2030 KL1333 is goedgekeurd en gaat draaien dan lachen we om de koers van nu.
0 · Reply
Funtoers
Funtoers Aug. 4 at 5:37 PM
$PHAR looks good!
0 · Reply
Ruconestor
Ruconestor Aug. 4 at 5:25 PM
$PHAR Extremely bullish.
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 1 at 10:52 AM
$MTLS $SLS $TREE $FORR $PHAR Mixed Moves Across Sectors $MTLS $SLS $TREE $FORR $PHAR in Focus $MTLS: eyes on additive manufacturing momentum $SLS: biotech bounce or just a head-fake? $TREE: fintech struggles but insiders nibbling $FORR: research firm under pressure post-Q2 miss $PHAR: specialty pharma name testing breakout levels Watch for catalysts these tickers are moving with intent. https://analyticainvestor.beehiiv.com/p/figma-flys-25e976f618c747ce
0 · Reply
Noobnr1
Noobnr1 Jul. 31 at 8:19 AM
$PHAR 🚀 Very nice and rising results 🚀 $PFE $DVAX $GILD 💎💎💎
0 · Reply
BGG13
BGG13 Jul. 31 at 6:11 AM
$PHAR Earnings Q2 2025, Cheers! https://www.pharming.com/sites/default/files/imce/Press%20releases/Pharming%20reports%202Q_1H%202025%20financial%20results_EN_31JUL25.pdf
0 · Reply
janisbr
janisbr Jul. 30 at 12:25 PM
$PHAR wat een drol van een aandeel zeg
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 21 at 6:07 PM
Oil & Gas Co. to Start New Drill Program This Quarter https://ow.ly/BibG50WsQIM Pharos Energy Plc plans to drill in two fields in Vietnam, four wells in one, starting in Q3/25, two in the other, beginning in Q4/25, noted an Auctus Advisors report. $PHAR
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 10 at 5:04 PM
$KALV ‘s gain is $PHAR loss. 📊
0 · Reply
Latest News on PHAR
Pharming Group to participate in August investor conference

Aug 4, 2025, 2:00 AM EDT - 2 days ago

Pharming Group to participate in August investor conference

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 3:04 PM EDT - 4 days ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 31, 2025, 1:00 AM EDT - 6 days ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jul 17, 2025, 2:00 AM EDT - 20 days ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 24, 2025, 1:00 AM EDT - 6 weeks ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Jun 11, 2025, 11:15 AM EDT - 7 weeks ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Pharming Group to participate in June investor conferences

May 28, 2025, 2:00 AM EDT - 2 months ago

Pharming Group to participate in June investor conferences

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:50 AM EDT - 3 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

Pharming Group reports first quarter 2025 financial results and provides business update

May 8, 2025, 1:00 AM EDT - 3 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 30, 2025, 11:45 AM EDT - 3 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group to report first quarter 2025 financial results on May 8

Apr 24, 2025, 2:00 AM EDT - 3 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 23, 2025, 3:30 AM EDT - 3 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Apr 3, 2025, 1:00 AM EDT - 4 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Mar 28, 2025, 3:00 AM EDT - 4 months ago

Pharming Group to participate in April investor conferences

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:44 PM EDT - 5 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 13, 2025, 2:00 AM EDT - 5 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Mar 4, 2025, 9:15 AM EST - 5 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Feb 7, 2025, 4:00 PM EST - 6 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 12:00 PM EST - 7 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Jan 21, 2025, 1:00 AM EST - 7 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 15, 2024, 1:45 PM EST - 8 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Dec 11, 2024, 9:34 AM EST - 8 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Pharming Group to participate in November investor conference

Nov 5, 2024, 2:00 AM EST - 9 months ago

Pharming Group to participate in November investor conference

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:44 PM EDT - 10 months ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 2:00 AM EDT - 10 months ago

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Oct 10, 2024, 1:00 AM EDT - 10 months ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 26, 2024, 1:00 AM EDT - 11 months ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming Group to participate in September investor conferences

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Pharming Group to report second quarter and first half 2024 financial results on August 1

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Pharming Group to participate in May investor conference

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Apr 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 1:15 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Pharming Group reports fourth quarter and full year 2023 financial results

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2023 financial results

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Feb 29, 2024, 2:00 AM EST - 1 year ago

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Pharming Group to participate in February investor conferences

Feb 8, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in February investor conferences

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Jan 8, 2024, 1:00 AM EST - 1 year ago

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Dec 13, 2023, 1:00 AM EST - 1 year ago

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

SannieVerraderlijk
SannieVerraderlijk Aug. 6 at 8:15 AM
$ABVX $PHAR Will start building bigger positions in EU bio's on any dips
0 · Reply
Longterm007
Longterm007 Aug. 5 at 6:45 AM
$PHAR exact, en als in 2030 KL1333 is goedgekeurd en gaat draaien dan lachen we om de koers van nu.
0 · Reply
Funtoers
Funtoers Aug. 4 at 5:37 PM
$PHAR looks good!
0 · Reply
Ruconestor
Ruconestor Aug. 4 at 5:25 PM
$PHAR Extremely bullish.
0 · Reply
AnalyticaInvestor
AnalyticaInvestor Aug. 1 at 10:52 AM
$MTLS $SLS $TREE $FORR $PHAR Mixed Moves Across Sectors $MTLS $SLS $TREE $FORR $PHAR in Focus $MTLS: eyes on additive manufacturing momentum $SLS: biotech bounce or just a head-fake? $TREE: fintech struggles but insiders nibbling $FORR: research firm under pressure post-Q2 miss $PHAR: specialty pharma name testing breakout levels Watch for catalysts these tickers are moving with intent. https://analyticainvestor.beehiiv.com/p/figma-flys-25e976f618c747ce
0 · Reply
Noobnr1
Noobnr1 Jul. 31 at 8:19 AM
$PHAR 🚀 Very nice and rising results 🚀 $PFE $DVAX $GILD 💎💎💎
0 · Reply
BGG13
BGG13 Jul. 31 at 6:11 AM
$PHAR Earnings Q2 2025, Cheers! https://www.pharming.com/sites/default/files/imce/Press%20releases/Pharming%20reports%202Q_1H%202025%20financial%20results_EN_31JUL25.pdf
0 · Reply
janisbr
janisbr Jul. 30 at 12:25 PM
$PHAR wat een drol van een aandeel zeg
0 · Reply
StreetwiseReports
StreetwiseReports Jul. 21 at 6:07 PM
Oil & Gas Co. to Start New Drill Program This Quarter https://ow.ly/BibG50WsQIM Pharos Energy Plc plans to drill in two fields in Vietnam, four wells in one, starting in Q3/25, two in the other, beginning in Q4/25, noted an Auctus Advisors report. $PHAR
0 · Reply
BiotechBonesaw
BiotechBonesaw Jul. 10 at 5:04 PM
$KALV ‘s gain is $PHAR loss. 📊
0 · Reply
Ruconestor
Ruconestor Jul. 7 at 1:33 PM
$PHAR Dan weet je toch genoeg . Ruconest( c1 inhibitor )is het Breedste veiligste , snelste en best werkende middel tot nu toe voor behandeling HAE
0 · Reply
Ruconestor
Ruconestor Jul. 7 at 1:26 PM
$PHAR 4. Duur en beschikbaarheid • Lanadelumab (Takhzyro), een monoklonaal antilichaam tegen plasma-kallikreïne, is zeer duur en kan logistiek uitdagender zijn in vergelijking met C1-INH-producten, die al langer op de markt zijn. • Niet alle kalikreïneremmers zijn wereldwijd beschikbaar of vergoed. ⸻ 5. Langetermijndata • C1-inhibitoren hebben een langer track record qua veiligheid en effectiviteit. • Kalikreïneremmers zijn relatief nieuw (bijv. lanadelumab sinds 2018) en hoewel studies positief zijn, is er minder langetermijnervaring.
0 · Reply
Ruconestor
Ruconestor Jul. 7 at 1:24 PM
$PHAR ⸻ 2. Geen effect bij andere vormen van HAE • Kalikreïneremmers zijn vooral effectief bij HAE type I en II (bradykinine-gemedieerd). • Ze zijn mogelijk minder bruikbaar bij HAE met normale C1-INH (zgn. nC1-INH-HAE), waar de pathogenese anders kan zijn. ⸻ 3. Immuunreacties/allergieën (bij bepaalde middelen) • Bij ecallantide (een subcutane kallikreïneremmer) bestaat een risico op anafylaxie (~3%), wat betekent dat het alleen onder medische supervisie mag worden toegediend. • Dit risico bestaat niet bij C1-inhibitorpreparaten.
0 · Reply
Ruconestor
Ruconestor Jul. 7 at 1:21 PM
$PHAR Nadeel van een kalikreïneremmer t.o.v. een C1-inhibitor Hoewel kalikreïneremmers effectief zijn bij het voorkomen van aanvallen van HAE, zijn er een aantal nadelen ten opzichte van C1-inhibitoren: ⸻ 1. Beperkter werkingsmechanisme • C1-inhibitoren grijpen breder in op het complement- en contactactivatiesysteem (waaronder C1, kallikreïne en factor XIIa), en richten zich op de onderliggende oorzaak van HAE type I en II. • Kalikreïneremmers blokkeren slechts één stap in de keten: de omzetting van hoog-moleculair-gewicht-kininogeen (HMWK) naar bradykinine via kallikreïne. Ze pakken dus een downstream-gevolg aan, niet de primaire deficiëntie. ➡️ Gevolg: Bij sommige patiënten kan dit betekenen dat C1-INH effectiever is, vooral bij acute aanvallen. ⸻
0 · Reply
Ruconestor
Ruconestor Jun. 30 at 3:36 PM
$PHAR Again excellent results for far more leniolisib patients.this stock Will explode . So much more VUS is so much more pharming medication.
1 · Reply
More_Rockets
More_Rockets Jun. 27 at 11:29 AM
$PHAR Any views from anyone regarding any pro/cons of owning Pharming stock via Amsterdam exhange versus Nasdaq? I bought $PHARM using IBKR traded on AEB, then noticed only afterwards that it's traded on Nasdaq as $PHAR.
0 · Reply
Ruconestor
Ruconestor Jun. 24 at 6:30 AM
$PHAR Excellent News on Leniolisib ( Joenja) Much more patients APDS will be defined. That will boost this stock ! Pharming will 🚀 up
1 · Reply
Noobnr1
Noobnr1 Jun. 10 at 9:43 AM
$CRSP $GILD $PFE $PHAR $DVAX Now is the time to shine 🤩🚀💎🌪️
0 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 9 at 2:03 PM
$KALV - Kalvista is still a buy ahead of their PDUFA $PHVS - Pharvaris is a hold well ahead of their HAE activity in 2026 $PHAR - I would sell or avoid this. Pharming will likely lose market shares or valuation with Kalvista’s expected approval & continued rise
1 · Reply
BiotechBonesaw
BiotechBonesaw Jun. 3 at 2:47 PM
$PHAR surprised this is running up ahead of $KALV approval in HAE. GLL biotech investors but I would avoid PHAR $ $PHVS until Kalvista does their thing
1 · Reply
Dutchindo
Dutchindo Jun. 3 at 8:18 AM
$PHAR 52 wk high 📈
0 · Reply
PenkeTrading
PenkeTrading May. 9 at 4:10 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Pharming Group NV. Is that bullish or bearish? $PHAR #Pharming #RsiOverbought #NASDAQ
0 · Reply